Author Archives: Isaura Santos

Two ALS Researchers Receive Sheila Essey Award

Robert Bowser from Barrow Neurological Institute and Adriano Chio from the University of Turin, Italy were recently awarded with the 2015 Sheila Essey Award by the American Academy of Neurology and the Amytrophic Lateral Sclerosis (ALS) Association. This award recognizes scientists’ research and contributions toward the prevention, management and eventual cure of ALS. Both researchers will receive the award…

MDA Hires ALS Scientific Program Officers For Its Team

The Muscular Dystrophy Association (MDA) continues to enhance its research and healthcare services programs and has recently hired two new Scientific Program Officers: Amanda Haidet-Phillips and Laura Hagerty, both Ph.D. They will be reporting to Grace Pavlath, also Ph.D, who joined MDA in the past year to be the Scientific Program Director…

Prof. Stephen Hawking Receives “Beacon Of Courage And Dedication Award” from Society For Brain Mapping & Therapeutics

The Society for Brain Mapping and Therapeutics (SMBT) 12th Annual World Congress Black Tie Gala was held on Saturday, March 7, 2015 at the Los Angeles Millennium Biltmore Hotel, Los Angeles, CA, during which the Society awarded the “Beacon of Courage and Dedication Award” to Professor Stephen Hawking — a living ALS medical miracle. Recorded on…

OptiKira To Develop Cell-Protective Therapeutics For Unfolded Protein Response

BioMotiv is a drug advancement accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle working on breakthrough discoveries and new therapeutics that have the potential to address unmet clinical needs. Recently, the accelerator announced the creation of a platform company, OptiKira, that will…

Treeway Collaborates with uniQure to Create Gene Therapy For ALS

Treeway, a biotechnological company based in the Netherlands, founded by Bernard Muller and Robbert Jan Stuit, who are both entrepreneurs and both diagnosed with amyotrophic lateral sclerosis (ALS), recently announced a collaboration with uniQure, a Dutch company specialized in gene therapy to develop a treatment for the disease.

AB Science Will Continue Phase 3 Study Of Masitinib For ALS

AB Science SA, a pharmaceutical company focused on research, advancement and commercialization of protein kinase inhibitors (PKIs) announced that the external Data and Safety Monitoring Board (DSMB) recommended the company’s phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) be continued. The decision was supported by the drug’s latest safety reports. The current…

Biogen Idec and Columbia Partner For ALS Genetics Research

A $30 million alliance between Biogen Idec and Columbia University Medical Center was formed to conduct research in genetics and to understand the underlying causes of several diseases such as amyotrophic lateral sclerosis (ALS). This new partnership may help identify new treatment approaches to address the largely unmet clinical needs…